Verastem eyes accelerated approval for KRAS G12D drug in 3 cancers; ADC Therapeutics cuts 17% of staff in restructuring.
June 24, 2026 10:17 AM EDT
News Briefing
Verastem's KRAS G12D vision; ADC Therapeutics reorganizes, lays off 17% of staff
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders…
With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line…
Cartesian’s $150M financing; Editas Medicine’s money moves
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3…
